Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Would you recommend XRT to post-cystectomy bladder cancer patient with metastatic PA and mesenteric nodes?
Answer from: Radiation Oncologist at Community Practice
I would not as this would have outcome like metastatic disease and need systemic treatment as the mainstay of treatment.
Sign in or Register to read more
12776
Related Questions
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
In asymptomatic patients with castrate resistant prostate cancer who have failed chemotherapy and have progressive vertebral body metastases, when do you prescribe lutetium-177 vs prophylactic spinal radiation?
For patients with metastatic RCC and gross hematuria from the primary tumor, what palliative radiation regimen would you recommend to help control the bleeding?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
Do you ever dose escalate radiotherapy to the primary in low volume metastatic prostate cancer?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
What is your preferred dose to gross lymph nodes when treating non-metastatic high-risk prostate cancer?
Do you use an age cutoff for prostate brachytherapy?
For a patient with a rising PSA after prostatectomy with seminal vesicles being negative for disease at surgery, do you ever treat the prostate bed and seminal vesicle bed with different doses in an SIB plan?
Why do the most recent NCCN guidelines (Version 4.2024, 05/17/24) omit the duration of ADT for high-risk prostate cancer patients?